Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin

ConclusionThis is the first study to assess the utility of RETeval ™ device in children under 3 years of age undergoing vigabatrin treatment. RETeval™ demonstrated high intra-visit reliability with responses consistent with the standard Espion ERG. RETeval™ may be beneficial for assessment of retinal toxicity in young children treated with vigabatrin.

http://link.springer.com/10.1007/s10633-019-09684-9

Source: Documenta Ophthalmologica - March 1, 2019 Category: Opthalmology Source Type: research